Pooled analysis results indicated that higher β2M levels in DLBCL patients were associated with shorter PFS (HR Pooled: 1.54, 95% CI: 1.39–1.70, p‐value < 0.01) (Figure 3). The gene discussed is B2M; the disease is diffuse large B-cell lymphoma.